The finding of this study was also in hormony with our previous study (Tikoo et al., 2009b) in which we had tried rosiglitazone as a PPAR-γ agonist in combination with CIS as an anticancer cancer agent in DMBA induced breast cancer in rats. The gene discussed is PPARG; the disease is in situ carcinoma.